Target | Tools/compounds | Disease | Summary of study | References |
---|---|---|---|---|
Ligands | ||||
WNT-1 | CCSP-driven WNT-1 overexpression (in vivo) | Asthma |
| 89 |
WNT-5A | Recombinant protein (in vitro) | IPF/fibrosis |
| 74 |
Recombinant protein (in vitro) | Physiological conditions |
| 69 | |
Surfactant protein C (SPC)-driven WNT-5A overexpression, recombinant protein, neutralising antibodies (in vitro and in vivo) | COPD |
| 110 | |
Receptors | ||||
LRP5 | LRP5−/− mice and siRNA (in vitro and in vivo) | IPF/fibrosis |
| 44 |
FZD4 | FzM1, FZD4 siRNA and overexpression (in vitro) | COPD |
| 112 |
FZD8 | FZD8−/− mice and siRNA (in vitro and in vivo) | IPF/fibrosis |
| 71 |
COPD |
| 123 | ||
Intercellular proteins | ||||
FAM13A | FAM13A−/− mice (in vivo) | COPD |
| 111 |
GSK-3β | LiCl (in vitro) | IPF/fibrosis/COPD |
| 63 |
LiCl (in vivo) | COPD |
| 109 | |
SB216763 (in vivo) | COPD |
| 125 | |
CT99021 or LiCl (ex vivo) | COPD |
| 115 | |
Tankyrases | XAV939 (in vivo and in vitro) | IPF/fibrosis |
| 45 |
β-catenin | siRNA (in vivo) | Asthma |
| 90 |
β-catenin interaction | ||||
β-catenin/TCF | ICAT (in vitro) | Physiological conditions |
| 48 |
β-catenin/TCF | PKF115–584 (in vitro) | Physiological conditions |
| 50 |
Physiological conditions |
| 95 | ||
Physiological conditions |
| 97 | ||
Physiological conditions |
| 96 | ||
β-catenin/CBP | ICG-001 (in vitro and in vivo) | Asthma |
| 94 |
ICG-001 (in vivo) | IPF |
| 42 | |
β-catenin/p300 | IQ-1 (in vitro) | Physiological conditions |
| 69 |
WNT target gene | ||||
WISP1 | WISP1 neutralising antibodies (in vitro and in vivo) | IPF |
| 35 |
Asthma |
| 93 |
3D-LTCs, three-dimensional lung tissue cultures; AHR, airway hyper-responsiveness; ATI (or II), alveolar epithelial type I (or II) cells; CBP, cAMP response element-binding protein binding protein; CCSP, Clara cell secretory protein; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; FZD, Frizzled receptor; GSK-3, glycogen synthase kinase-3; ICAT, inhibitor of β-catenin and TCF; IPF, idiopathic pulmonary fibrosis; LRP5−/−, mice lacking lipoprotein receptor-related protein 5; OVA, ovalbumin; SNP, single nucleotide polymorphism; TCF, T cell factor; WISP1, WNT1-inducible signalling protein-1.